Iduronate Sulfatase Protein
| Property | Details |
|----------|---------|
| Protein Name | Iduronate sulfatase |
| Gene | IDS |
| Chromosome Location | Xq28 |
| UniProt ID | P22304 |
| Molecular Weight | 56 kDa (precursor); 52-54 kDa (mature) |
| Enzyme Classification | Sulfatase (EC 3.1.6.1) |
| Cellular Localization | Lysosome |
Overview
Iduronate sulfatase (IDS) is a lysosomal sulfatase enzyme responsible for the catabolism of glycosaminoglycans (GAGs), particularly dermatan sulfate and heparan sulfate. The protein is encoded by the IDS gene located on chromosome Xq28, making it an X-linked gene. The enzyme exists as a ~56 kDa precursor protein that undergoes post-translational modifications, including proteolytic processing and formylation of active site cysteine residues, to generate the mature 52-54 kDa catalytically active form. IDS is primarily synthesized in liver, bone marrow, and other tissues, then transported to lysosomes where it functions within the degradation pathway of sulfated glycans.
Function/Biology
Iduronate sulfatase catalyzes the removal of sulfate groups from iduronate residues in heparan sulfate and dermatan sulfate, which are major components of the extracellular matrix and cell surface proteoglycans. This desulfation step is a critical early event in the sequential degradation of these GAGs within the lysosomal compartment. The enzyme works in concert with other sulfatases and glycosidases to completely degrade these polymers into monosaccharides.
...Iduronate Sulfatase Protein
| Property | Details |
|----------|---------|
| Protein Name | Iduronate sulfatase |
| Gene | IDS |
| Chromosome Location | Xq28 |
| UniProt ID | P22304 |
| Molecular Weight | 56 kDa (precursor); 52-54 kDa (mature) |
| Enzyme Classification | Sulfatase (EC 3.1.6.1) |
| Cellular Localization | Lysosome |
Overview
Iduronate sulfatase (IDS) is a lysosomal sulfatase enzyme responsible for the catabolism of glycosaminoglycans (GAGs), particularly dermatan sulfate and heparan sulfate. The protein is encoded by the IDS gene located on chromosome Xq28, making it an X-linked gene. The enzyme exists as a ~56 kDa precursor protein that undergoes post-translational modifications, including proteolytic processing and formylation of active site cysteine residues, to generate the mature 52-54 kDa catalytically active form. IDS is primarily synthesized in liver, bone marrow, and other tissues, then transported to lysosomes where it functions within the degradation pathway of sulfated glycans.
Function/Biology
Iduronate sulfatase catalyzes the removal of sulfate groups from iduronate residues in heparan sulfate and dermatan sulfate, which are major components of the extracellular matrix and cell surface proteoglycans. This desulfation step is a critical early event in the sequential degradation of these GAGs within the lysosomal compartment. The enzyme works in concert with other sulfatases and glycosidases to completely degrade these polymers into monosaccharides.
The catalytic mechanism involves a post-translationally modified active site containing a formylglycine (FGly) residue, derived from a conserved cysteine. This unique catalytic center enables the nucleophilic attack on the sulfate ester bonds. The enzyme exhibits pH optimum around 4.5-5.0, consistent with the lysosomal environment, and requires no organic cofactors for activity.
IDS localizes to lysosomes through a combination of mechanisms: synthesis on ribosomes in the rough endoplasmic reticulum, transit through the Golgi apparatus where mannose-6-phosphate residues are added, and subsequent binding to mannose-6-phosphate receptors that direct trafficking to lysosomes. A smaller percentage of the enzyme is secreted and can be taken up by other cells through mannose-6-phosphate receptor-mediated endocytosis, allowing intercellular enzyme distribution.
Role in Neurodegeneration
Mutations in the IDS gene cause Hunter syndrome (mucopolysaccharidosis II, MPS II), an X-linked lysosomal storage disorder that frequently results in progressive neurological complications. Loss of IDS activity leads to accumulation of heparan sulfate and dermatan sulfate within lysosomes throughout the body, including in the central and peripheral nervous systems.
In the brain, GAG accumulation occurs in multiple cell types including microglia, astrocytes, and neurons, resulting in lysosomal dysfunction and secondary effects. Excessive lysosomal storage impairs cellular autophagy capacity, disrupts protein quality control mechanisms, and triggers neuroinflammation. Severe forms of Hunter syndrome cause progressive intellectual disability, behavioral changes, and dementia due to primary involvement of gray matter and progressive neuronal dysfunction.
Molecular Mechanisms
IDS deficiency triggers a cascade of pathological events. Accumulated GAGs alter lysosomal pH homeostasis and impair protease function, reducing overall proteolytic capacity. The buildup of storage material in microglia activates pro-inflammatory pathways including TLR signaling and inflammasome activation, promoting neuroinflammation through increased production of IL-1β and TNF-α.
Additionally, GAG accumulation may directly affect protein aggregation dynamics. Secondary accumulation of proteins that would normally be degraded—including misfolded proteins and potential amyloidogenic species—creates an environment that may accelerate neurodegeneration pathways. In severe MPS II, compromise of white matter integrity occurs due to storage material in oligodendrocytes and disrupted myelin maintenance.
Clinical/Research Significance
Hunter syndrome manifests as two phenotypes: attenuated (non-neuropathic) and severe (neuropathic). Severe forms present in early childhood with rapidly progressive neurological decline, while attenuated forms show slower progression with variable neurological involvement. Over 600 IDS mutations have been identified, demonstrating substantial genetic heterogeneity.
Current therapeutic strategies include enzyme replacement therapy (ERT) using recombinant idursulfase, which benefits somatic tissues but shows limited blood-brain barrier penetration. Gene therapy and substrate reduction therapy approaches are under investigation. High-dose ERT combined with intrathecal administration is being evaluated to improve CNS penetration and prevent neurological complications.
- Mucopolysaccharidosis II (Hunter syndrome) - Primary clinical manifestation of IDS deficiency